Key result
Ivabradine treatment improved ejection fraction and quality of life in a patient with inappropriate sinus tachycardia and ventricular dysfunction intolerant to conventional therapy.
Why the study?
Does ivabradine improve ejection fraction and quality of life in a patient with inappropriate sinus tachycardia and ventricular dysfunction?
Does ivabradine improve ejection fraction and quality of life in a patient with inappropriate sinus tachycardia and ventricular dysfunction?
Ivabradine improved ejection fraction and quality of life in a patient with inappropriate sinus tachycardia and ventricular dysfunction who was intolerant to conventional therapy.
Hypothesis-generating for ivabradine in refractory IST with LV dysfunction; controlled trials needed before practice change.
We present a case of a 49-year-old man with inappropriate sinus tachycardia and ventricular dysfunction. The conventional treatment (ace-inhibitor and beta-blockers) was not well tolerated by the patient, so Ivabradine, a specific inhibitor of If current in the sinus node, was started. After 3 months of using this medication, we observed an improvement of ejection fraction and quality of life.
No takes yet. Share an insight, caveat, or question.
Sette et al. (2010) studied this question. Ivabradine treatment improved ejection fraction and quality of life in a patient with inappropriate sinus tachycardia and ventricular dysfunction intolerant to conventional therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: